SKY0402
Phase 3Small molecule
Pacira Pharmaceuticals, IncSKY0402 is one of 86 small molecule programs targeting Hemorrhoid. It is currently in Phase 3.
3
Indications
15
Total Trials
0
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
275 competitors in Total Knee Arthroplasty
#DrugCompanyPhaseTrials
1SKY0402
Pacira Pharmaceuticals, IncPhase 3
Cymbalta
Alnylam PharmaceuticalsPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Xarelto
WWim Janssens
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Sufenta
LLeaf Vertical Inc.
Preclinical
EXPAREL
Pacira Pharmaceuticals, IncPreclinical
Nucynta
CCollegium Pharmaceutical, Inc.
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Zanaflex
LLegacy Health System
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hemorrhoid3 trials
Total Knee Arthroplasty2 trials
Inguinal hernia2 trials
Postoperative Analgesia2 trials
5 more indications
Hepatic Impairment1 trial
Local Infiltration1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SKY0402. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company